Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318
Oral versions of a cancer immunotherapy are showing early promise with manageable side effects across hundreds of patients, though response rates remain modest.
Three oral small-molecule PD-L1 inhibitors showed dose-dependent pharmacokinetics and target engagement (PD-L1 binding, T-cell activation); ORR ~9-11% across 424 total patients; INCB099280 and INCB099318 showed acceptable safety; INCB086550 discontinued due to immune-mediated peripheral neuropathy risk. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- phase1_clinical_trial
- Category
- novel_therapeutics
- Maturity
- Validated
- Journal
- Journal for ImmunoTherapy of Cancer
Why it surfaced
First comprehensive Phase I package for three oral small-molecule PD-L1 inhibitors—a potentially transformative delivery advance over intravenous checkpoint antibodies. Antitumor activity and target engagement confirmed; safety differentiation between compounds is clinically meaningful. Published in JITC with CC BY open access.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.